Fennec Pharmaceuticals, Inc. Q4 FY2024 earnings call

• Discussed the PEDMARK strategy with imperatives including increasing awareness of unmet need, establishing PEDMARK as standard-of-care, adoption beyond oncologists, ensuring access, and patient/caregiver activation. • Highlighted interest and adoption in the adolescent and young adult (AYA) segment, with key academic institutions like UCLA, Fred Hutchinson Cancer Center integrating PEDMARK. • Mentioned commercial launches outside the US, including with Norgine in Germany and the UK, and an investigator-initiated trial in Japan. • Progress on getting PEDMARK added to NCCN compendia, with submission for inclusion in neuroblastoma guidelines and anticipation of a decision by mid-2025. • Emphasized operational efficiency, with cash burn of $0.6 million in Q4 2024 and early debt repayment optimizing the balance sheet.

In the fourth quarter of 2024, the company reported $7.9 million in net product sales, a quarterly growth rate of approximately 13%. For the full fiscal year 2024, net product sales were $29.6 million compared to $21.3 million in 2023. The pediatric segment continues to show growth, and the AYA segment is an emerging significant opportunity, though specific revenue contribution percentages weren't broken down.

• Anticipates most significant quarter growth in the second half of 2025 as foundational pillars and initiatives impact PEDMARK growth. • Full year cash operating expenses expected to be similar to 2024, including step-up in marketing expenses and increased headcount, with elimination of pre-commercialization expenses related to Europe/Norgine. • Next milestone related to Norgine agreement is final pricing approval in Germany, with potential to receive milestones thereafter.

• Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ from forward-looking statements. Reference to these risks and uncertainties are in the press release and SEC filings. No specific operational failures detailed in the transcript beyond general risk disclosures.

Q: As it relates to Q4, can you give specifics on pediatric business sequential growth and AYA contribution?

A: Robert Andrade said they continue to see growth in the pediatric segment and AYA is an incredible opportunity but wouldn't break down details between contributions.

Q: Talk about second half inflection, NCCN compendia related, and AYA visibility. Can you give sense of 2025 growth potential for AYA?

A: Jeff Hackman said the opportunity is significant, growth will continue throughout 2025 as they build the business and invest, and they've seen growth in Q1 and expect it to continue.

Q: Progress of Norgine in Europe, relationships with key centers, rollout cadence, countries contributing to revenue, and AYA driver in Europe vs US?

A: Jeff Hackman said Norgine has the product commercially available in UK and Germany, working closely with Norgine, AYA is different in Europe with different structure, product approved for patients 1-month to 17 years in Europe.

Q: Competitive landscape for PEDMARK in US, price, SG&A, and label expansion clinical trials?

A: Robert Andrade talked about SG&A expenses, Jeff Hackman discussed PEDMARK pricing varying by patient, competitive landscape with compounded STS product mostly in pediatric settings, and said they'll update on label expansion developments.

Q: Japan trial data and partnering, and prioritization of commercial efforts between academic centers and community centers in AYA segment?

A: Jeff Hackman said they've had discussions about Japan partnering, data will inform value, and commercial efforts need to balance between academic centers and 4,000 community oncology practices as both are important for reaching AYA patients